Skip to Content

Notice

Prospective Grant of Exclusive License: Secreted Frizzled Related Protein-1 (sFRP-1) and derivatives thereof and their Use In Therapeutic Applications

A Notice by the National Institutes of Health on 10/12/2011

  • PDF
  • Document Details
  • Document Dates
  • Table of Contents
  • Public Comments
  • Regulations.gov Data
  • Sharing
  • Print
  • Document Statistics
  • Other Formats
Published Document: 2011-26343 (76 FR 63316)

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings

Document headings vary by document type but may contain the following:

  1. the agency or agencies that issued and signed a document
  2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  3. the agency docket number / agency internal file number
  4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

See the Document Drafting Handbook for more details.

Department of Health and Human Services
National Institutes of Health

AGENCY:

National Institutes of Health, Public Health Service, HHS.

ACTION:

Notice.

SUMMARY:

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the patents and patent applications belonging to the patent families having HHS Reference Numbers E-160-1997/0,/1,/2 and/3; E-014-2000/0; and E-060-2000/0, and/1. Specific details regarding the individual patents or patent applications which belong to these patent families are set forth in the table below:

Patent application number Country Filing date or international filing date Status Publication or patent number
60/050,417 US 5/29/1997 Abandoned N/A
60/050,495 US 6/23/1997 Abandoned N/A
09/087,031 US 5/29/1998 Issued 6,479,255
10/138,434 US 5/3/2002 Issued 7,183,377
PCT/US98/10974 PCT 5/29/1998 Expired WO 98/54325
09/546,043 US 4/10/2000 Issued 6,600,018
10/425,586 US 4/28/2003 Issued 7,223,853
11/748,872 US 5/15/2007 Issued 7,947,651
13/031,060 US 2/18/2011 Pending N/A
60/260,908 US 1/10/2001 Abandoned N/A
PCT/US02/00869 PCT 1/10/2002 Expired WO 02/055547
10/466,136 US 7/10/2003 Issued 7,488,710
12/019,567 US 1/24/2008 Pending 20080145884 A1
2002241859 AU 1/10/2002 Issued 2002241859
2,434,672 CA 1/10/2002 Pending 2,434,672
02 707454.1 EP 1/10/2002 Pending 1387854 A2
2002-556615 JP 1/10/2002 Issued 4029041
2007-120533 JP 1/10/2002 Issued 4248583
2008-169716 JP 1/10/2002 Issued 4248600

to Achelois BioSciences, Inc., a Delaware corporation having a place of business in Lexington, Massachusetts. The patent rights in these inventions have been assigned to the United States of America. In addition, the all of the rights associated with applications 09/546,043; 10/425,586; 11/748,872 and 13/031,060 are exclusively licensed to HHS by the co-owner the University of Massachusetts.

The prospective exclusive license territory may be “worldwide”, and the field of use may be limited to “use of sFRP-1 and derivatives thereof in the treatment of human disease.”

DATES:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2011 will be considered.

ADDRESSES:

Requests for copies of the patent applications, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Susan S. Rucker, JD, CLP, Senior Advisor for Intellectual Property Transactions, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4478; Facsimile: (301) 402-0220; E-mail: .

SUPPLEMENTARY INFORMATION:

The technology encompassed by the patents and/or patent applications (IP) to be included in this exclusive license relates to a protein designated s ecreted F rizzled R elated P rotein-1 (sFRP-1). sFRP-1, also known as SARP-2 (Secreted Apoptosis Related Protein-2). The IP covers various sFRP-1 compositions and uses thereof.

sFRP-1 is associated with Wnt signaling which has been implicated in a number of different processes including fibrosis (see, Hwang, I et al. Arch Pharm Res 32(12): 1653-62 (2009)) and bone remodeling (see, Hausler KD et al J Bone Miner Res 19(11) 1873-81 (Nov 2004). In addition, hypermethylation of the sFRP-1 promoter region, which leads to a loss of function and decreased sFRP-1 protein expression, has been linked to a number of cancers, including gastric cancer, esophageal adenocarcinoma, bladder cancer and head and neck squamous cell carcinoma (HNSCC).

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

( printed page 63317)

Dated: October 4, 2011.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011-26343 Filed 10-11-11; 8:45 am]

BILLING CODE 4140-01-P

Published Document: 2011-26343 (76 FR 63316)